Tuesday 28th April 2020

Approval of nintedanib for systemic sclerosis-associated interstitial lung disease

Nintedanib, a drug that slows the rate of lung fibrosis, has been approved as a treatment for individuals with systemic sclerosis-associated interstitial lung disease, the first option to have been made available.

Read Article

Thursday 4th April 2019

EZH2: what role does this molecule play in the progression of scleroderma?

Many scientific investigations concerning scleroderma focus on uncovering more about the processes that contribute to a person presenting symptoms. This is because if the driving factors behind it are defined, treatments can be applied to this area to limit the progression of the condition, either by blocking biological mechanisms or by obstructing involved molecules.

Read Article

Tuesday 25th April 2017

Focus on scleroderma and the heart at BSR annual meeting

Read Article

Tuesday 25th April 2017

European Scleroderma Observational Study

Read Article

Thursday 20th April 2017

c-Kit Pathway Influences Scleroderma Development

Read Article

Thursday 20th April 2017

Nailfold Capillaroscopy as a Research Tool

Read Article

Thursday 20th April 2017

Identifying Life-Threatening Arrhythmias in Scleroderma

Read Article

Thursday 20th April 2017

Treatment of Bowel Dysfunction in Scleroderma

Read Article

Tuesday 26th April 2016

Drug-induced Raynaud’s phenomenon is ‘probably underestimated'

Raynaud's phenomenon can be triggered or worsened by certain drugs, such as beta blockers. But knowledge about the condition is limited.

Read Article

Tuesday 26th April 2016

M10 Peptide Shows Anti-Fibrotic Activity in Mice

Researchers recently discovered a natural molecule, the M10 peptide, that can significantly decrease fibrosis in a mouse model of scleroderma.

Read Article